The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-18
DOI
10.1038/s41573-022-00391-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The cortical origin and initial spread of medial temporal tauopathy in Alzheimer’s disease assessed with positron emission tomography
- (2021) Justin S. Sanchez et al. Science Translational Medicine
- Atomic-level differences between brain parenchymal- and cerebrovascular-seeded Aβ fibrils
- (2021) Kathryn P. Scherpelz et al. Scientific Reports
- Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
- (2021) Henrik Zetterberg et al. Molecular Neurodegeneration
- Donanemab in Early Alzheimer’s Disease
- (2021) Mark A. Mintun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of Aducanumab for Alzheimer Disease
- (2021) G. Caleb Alexander et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease
- (2021) Jing Qian et al. NEUROLOGY
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
- (2021) Chad J. Swanson et al. Alzheimers Research & Therapy
- Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
- (2021) Jeffrey Cummings et al. Alzheimers Research & Therapy
- The Problem of Aducanumab for the Treatment of Alzheimer Disease
- (2021) G. Caleb Alexander et al. ANNALS OF INTERNAL MEDICINE
- Aducanumab: What about the Patient?
- (2021) Ronald C. Petersen ANNALS OF NEUROLOGY
- Biomarkers for neurodegenerative diseases
- (2021) Oskar Hansson NATURE MEDICINE
- A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
- (2021) Stephen Salloway et al. NATURE MEDICINE
- Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease
- (2021) Stephen Salloway et al. NEUROLOGY
- Controversy and Progress in Alzheimer’s Disease — FDA Approval of Aducanumab
- (2021) Gil D. Rabinovici NEW ENGLAND JOURNAL OF MEDICINE
- Revisiting FDA Approval of Aducanumab
- (2021) G. Caleb Alexander et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Appropriate Use of Accelerated Approval — Aducanumab for Alzheimer’s Disease
- (2021) Billy Dunn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Approval of Aducanumab for Alzheimer Disease—the FDA’s Perspective
- (2021) Billy Dunn et al. JAMA Internal Medicine
- The Accelerated Approval of Aducanumab for Treatment of Patients With Alzheimer Disease
- (2021) Robert Steinbrook JAMA Internal Medicine
- The β-secretase BACE1 in Alzheimer’s disease
- (2020) Harald Hampel et al. BIOLOGICAL PSYCHIATRY
- Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET
- (2020) Renaud La Joie et al. Science Translational Medicine
- Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
- (2020) Kenta Yoshida et al. Alzheimers Research & Therapy
- Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease
- (2020) Sanka Amadoru et al. Alzheimers Research & Therapy
- Amyloid β-protein and beyond: the path forward in Alzheimer’s disease
- (2020) Dominic M Walsh et al. CURRENT OPINION IN NEUROBIOLOGY
- The implications of different approaches to define AT(N) in Alzheimer disease
- (2020) Niklas Mattsson-Carlgren et al. NEUROLOGY
- The coevolution of atomic resolution and whole-brain imaging for tau neurofibrillary tangles
- (2020) Raeann M. Dalton et al. ACS Chemical Neuroscience
- Synergy between amyloid-β and tau in Alzheimer’s disease
- (2020) Marc Aurel Busche et al. NATURE NEUROSCIENCE
- Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease
- (2020) Amy F. T. Arnsten et al. Alzheimers & Dementia
- Predicting future rates of tau accumulation on PET
- (2020) Clifford R Jack et al. BRAIN
- Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment
- (2020) David S. Knopman et al. JAMA Neurology
- Tau PET imaging in neurodegenerative tauopathies—still a challenge
- (2019) Antoine Leuzy et al. MOLECULAR PSYCHIATRY
- Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology
- (2019) Vincent Doré et al. Alzheimers & Dementia
- A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia
- (2019) Michael J Pontecorvo et al. BRAIN
- Progressive tau accumulation in Alzheimer’s disease: two-year follow-up study
- (2019) Hanna Cho et al. JOURNAL OF NUCLEAR MEDICINE
- Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease
- (2019) Michael F. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Target Engagement in an Alzheimer Trial: Crenezumab Lowers Aβ Oligomers in CSF
- (2019) Ting Yang et al. ANNALS OF NEUROLOGY
- Determining clinically meaningful decline in preclinical Alzheimer disease
- (2019) Philip S. Insel et al. NEUROLOGY
- Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults
- (2019) Val J. Lowe et al. NEUROLOGY
- Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography
- (2019) Niklas Mattsson et al. JAMA Neurology
- Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease
- (2019) Bernard J. Hanseeuw et al. JAMA Neurology
- Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
- (2019) Sebastian Palmqvist et al. EMBO Molecular Medicine
- Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
- (2019) Gregory Klein et al. Alzheimers Research & Therapy
- Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ
- (2019) William J. Meilandt et al. Alzheimers Research & Therapy
- Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer’s disease brain
- (2018) Wei Hong et al. ACTA NEUROPATHOLOGICA
- Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale
- (2018) Michael Navitsky et al. Alzheimers & Dementia
- Longitudinal tau PET in ageing and Alzheimer’s disease
- (2018) Clifford R Jack et al. BRAIN
- Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
- (2018) Victor L. Villemagne et al. Nature Reviews Neurology
- Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease
- (2018) Michael F. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
- (2018) Lawrence S. Honig et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease
- (2018) Guoqiao Wang et al. STATISTICS IN MEDICINE
- Brain Shuttle Antibody for Alzheimer’s Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode
- (2018) Felix Weber et al. Cell Reports
- The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease
- (2018) Holly M. Brothers et al. Frontiers in Aging Neuroscience
- Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
- (2018) Bernd Bohrmann et al. JOURNAL OF ALZHEIMERS DISEASE
- Imaging the evolution and pathophysiology of Alzheimer disease
- (2018) William Jagust NATURE REVIEWS NEUROSCIENCE
- Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease
- (2018) Andrew J. Aschenbrenner et al. NEUROLOGY
- Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)
- (2018) Stephen Salloway et al. Alzheimers Research & Therapy
- Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology
- (2018) Renaud La Joie et al. Alzheimers & Dementia
- In vivo staging of regional amyloid deposition
- (2017) Michel J. Grothe et al. NEUROLOGY
- A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
- (2017) Susanne Ostrowitzki et al. Alzheimers Research & Therapy
- SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F-18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A β-AMYLOID PLAQUE-SPECIFIC ANTIBODY, IN ALZHEIMER’S DISEASE (AD)
- (2016) Michael C. Irizarry et al. Alzheimers & Dementia
- Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
- (2016) Eric R. Siemers et al. Alzheimers & Dementia
- The Cellular Phase of Alzheimer’s Disease
- (2016) Bart De Strooper et al. CELL
- ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
- (2016) Jinping Wang et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- Notch signalling in context
- (2016) Sarah J. Bray NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
- (2016) Veronika Logovinsky et al. Alzheimers Research & Therapy
- Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin
- (2016) Mark Ultsch et al. Scientific Reports
- The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET
- (2015) William E. Klunk et al. Alzheimers & Dementia
- Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
- (2015) Osama Sabri et al. Alzheimers & Dementia
- Prevalence of Amyloid PET Positivity in Dementia Syndromes
- (2015) Rik Ossenkoppele et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia
- (2015) Willemijn J. Jansen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Amyloid-β11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials
- (2015) Enchi Liu et al. NEUROLOGY
- Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease
- (2015) Rachelle S Doody et al. Alzheimers Research & Therapy
- Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density
- (2015) Craig Curtis et al. JAMA Neurology
- Primary age-related tauopathy (PART): a common pathology associated with human aging
- (2014) John F. Crary et al. ACTA NEUROPATHOLOGICA
- A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease
- (2014) Eric Karran et al. ANNALS OF NEUROLOGY
- Lessons from a Failed γ-Secretase Alzheimer Trial
- (2014) Bart De Strooper CELL
- Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle
- (2014) Jens Niewoehner et al. NEURON
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- (2014) Stephen Salloway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
- (2014) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Preclinical Alzheimer Cognitive Composite
- (2014) Michael C. Donohue et al. JAMA Neurology
- Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
- (2013) Victor L Villemagne et al. LANCET NEUROLOGY
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
- (2013) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques
- (2012) Ira Driscoll et al. ACTA NEUROPATHOLOGICA
- Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
- (2012) Martin Farlow et al. Alzheimers & Dementia
- Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
- (2012) Christopher M Clark et al. LANCET NEUROLOGY
- A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
- (2012) Thorlakur Jonsson et al. NATURE
- The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
- (2012) Iryna Benilova et al. NATURE NEUROSCIENCE
- A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
- (2012) Ronald B. DeMattos et al. NEURON
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
- (2011) Susanne Ostrowitzki ARCHIVES OF NEUROLOGY
- Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
- (2011) Heiko Braak et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
- (2011) Eric Karran et al. NATURE REVIEWS DRUG DISCOVERY
- Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis
- (2010) Delphine Boche et al. ACTA NEUROPATHOLOGICA
- A γ-secretase inhibitor decreases amyloid-β production in the central nervous system
- (2009) Randall J. Bateman et al. ANNALS OF NEUROLOGY
- Visualization of Brain Amyloid and Microglial Activation in Mouse Models of Alzheimers Disease
- (2009) Makoto Higuchi Current Alzheimer Research
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
- (2009) Clifford R Jack et al. LANCET NEUROLOGY
- An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease
- (2009) Anna Lord et al. NEUROBIOLOGY OF DISEASE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started